Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04767724
Other study ID # LH2017-012
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 10, 2018
Est. completion date April 10, 2020

Study information

Verified date February 2021
Source Chinese Medical Association
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This RCT is to investigate the clinical effect of extracorporeal shock wave therapy (ESWT) compared to the local corticosteroid injection (LCI) in managing mild to moderate carpal tunnel syndrome (CTS).


Description:

To investigate the effect of extracorporeal shock wave therapy (ESWT) compared to the local corticosteroid injection (LCI) in managing mild to moderate carpal tunnel syndrome (CTS). About 50-60 patients with mild to moderate CTS are supposed to be randomly allocated into either ESWT group or LCI group. The outcomes include the visual analog scale (VAS), the Boston Carpal Tunnel Questionnaire (BCTQ), and nerve conduction study at baseline and at 3 weeks, 9 weeks, 12 weeks, 6 months, and 12 months after the treatments.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date April 10, 2020
Est. primary completion date August 2, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: The patients aged =18 years 1. Should present a new episode of CTS with symptoms lasting for = six weeks 2. Symptoms include wrist pain, numbness, and paraesthesia on the hands 3. Tested postive by the Phalen test and Tinel test 4. Electrodiagnostically diagnosed with mild to moderate CTS Exclusion Criteria: 1. A lack of consent information 2. A history of a CTS surgery or LCI in the carpal tunnel 3. Asystemic disease that may interfere with the study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Extracorporeal shock wave
Participants received 3 ESWT sessions once per week for 3 consecutive weeks or a single injection of one mL (40 mg) of betamethasone into the region surrounding the median nerve.

Locations

Country Name City State
China Ningbo Medical Center Lihuili Hospital Ningbo Zhejiang ZJ

Sponsors (1)

Lead Sponsor Collaborator
Chinese Medical Association

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is frequently used as a tool to measure the degree of the pain felt by the participants. The score ranges from 0 to 10. The higher score means a higher degree of the pain. At baseline (before the treatment)
Primary Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is frequently used as a tool to measure the degree of the pain felt by the participants. The score ranges from 0 to 10. The higher score means a higher degree of the pain. At 6 months after the treatments
Primary Visual Analog Scale (VAS) The Visual Analog Scale (VAS) is frequently used as a tool to measure the degree of the pain felt by the participants. The score ranges from 0 to 10. The higher score means a higher degree of the pain. At 12 months after the treatments
Primary Boston Carpal Tunnel Questionnaire (BCTQ) Boston Carpal Tunnel Questionnaire (BCTQ) is the most widely used self-administered outcome scale in patients with carpal tunnel syndrome (CTS) for assessing patients' perceived symptom severity and functional status. The score ranges from 19 to 95. The higher score means a worse status of CTS. At baseline (before the treatment)
Primary Boston Carpal Tunnel Questionnaire (BCTQ) Boston Carpal Tunnel Questionnaire (BCTQ) is the most widely used self-administered outcome scale in patients with carpal tunnel syndrome (CTS) for assessing patients' perceived symptom severity and functional status. The score ranges from 19 to 95. The higher score means a worse status of CTS. At 6 months after the treatments
Primary Boston Carpal Tunnel Questionnaire (BCTQ) Boston Carpal Tunnel Questionnaire (BCTQ) is the most widely used self-administered outcome scale in patients with carpal tunnel syndrome (CTS) for assessing patients' perceived symptom severity and functional status. The score ranges from 19 to 95. The higher score means a worse status of CTS. At 12 months after the treatments
Primary The peak latency of the median sensory nerve action potential (SNAP) The peak latency of the median sensory nerve action potential (SNAP) is used to assess the function status of the median sensory nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At baseline (before the treatment)
Primary The peak latency of the median sensory nerve action potential (SNAP) The peak latency of the median sensory nerve action potential (SNAP) is used to assess the function status of the median sensory nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At 6 months after the treatments
Primary The peak latency of the median sensory nerve action potential (SNAP) The peak latency of the median sensory nerve action potential (SNAP) is used to assess the function status of the median sensory nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At 12 months after the treatments
Primary The amplitude of the median sensory nerve action potential The amplitude of the median sensory nerve action potential is used to assess the function status of the median sensory nerve. The value ranges from 0 µV. The higher value means the better function status of the nerve. At baseline (before the treatment)
Primary The amplitude of the median sensory nerve action potential The amplitude of the median sensory nerve action potential is used to assess the function status of the median sensory nerve. The value ranges from 0 µV. The higher value means the better function status of the nerve. At 6 months after the treatments
Primary The amplitude of the median sensory nerve action potential The amplitude of the median sensory nerve action potential is used to assess the function status of the median sensory nerve. The value ranges from 0 µV. The higher value means the better function status of the nerve. At 12 months after the treatments
Primary The distal latency of the median compound motor action potential (CMAP) The distal latency of the median compound motor action potential (CMAP) is used to assess the function status of the median compound motor nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At baseline (before the treatment)
Primary The distal latency of the median compound motor action potential (CMAP) The distal latency of the median compound motor action potential (CMAP) is used to assess the function status of the median compound motor nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At 6 months after the treatments
Primary The distal latency of the median compound motor action potential (CMAP) The distal latency of the median compound motor action potential (CMAP) is used to assess the function status of the median compound motor nerve. The value ranges from 0 ms. The less value means the quicker conduction of the action potential and the better function status of the nerve. At 12 months after the treatments
Primary The amplitude of the median compound motor action potential The amplitude of the median compound motor action potential is used to assess the function status of the median compound motor nerve. The value ranges from 0 mV. The higher value means the better function status of the nerve. At baseline (before the treatment)
Primary The amplitude of the median compound motor action potential The amplitude of the median compound motor action potential is used to assess the function status of the median compound motor nerve. The value ranges from 0 mV. The higher value means the better function status of the nerve. At 6 months after the treatments
Primary The amplitude of the median compound motor action potential The amplitude of the median compound motor action potential is used to assess the function status of the median compound motor nerve. The value ranges from 0 mV. The higher value means the better function status of the nerve. At 12 months after the treatments
See also
  Status Clinical Trial Phase
Completed NCT05067205 - Minimal Invasive Carpal Tunnel Release With the Novel Device N/A
Completed NCT03184688 - Platelet Rich Plasma for Carpal Tunnel Syndrome N/A
Completed NCT03582735 - Preoperative Neuromobilization Exercises for Individuals With Carpal Tunnel Syndrome N/A
Completed NCT05490420 - Effects of Upper Extremity Manual Lymphatic Drainage on Symptom Severity, Hand Functions, Electrophysiological and Ultrasonographic Measurements in Carpal Tunnel Syndrome N/A
Recruiting NCT05970692 - Cross-Cultural Adaptation and Psychometric Validation of the Turkish Version of Atroshi-Lyrén 6-item Symptoms Scale
Completed NCT04043780 - Clinical Validation of a Decompression Prototype Splint for Patients With Carpal Tunel Syndrome N/A
Completed NCT03880812 - Cost Information on Carpal Tunnel Syndrome Treatment Decisions N/A
Completed NCT06464809 - Treatment Intervention of Patients With Carpal Tunnel Syndrome (CTS) N/A
Recruiting NCT05503719 - An Absorbable Suture Versus a Non-absorbable Suture in Carpal Tunnel Release, a Randomized Controlled Trial N/A
Recruiting NCT05372393 - Carpal Tunnel Release Under Local Anaesthesia With or Without Distal Median Nerve Block N/A
Recruiting NCT05328180 - aDjunct bicarbonatE in Local anaesthesIa for CarpAl Tunnel rElease (DELICATE) N/A
Recruiting NCT05466162 - Soft Tissue Massage Along With Mobilization Technique on Symptoms and Functional Status of Carpal Tunnel Syndrome N/A
Completed NCT04060875 - Research Protocol for Karuna Labs Inc.: Safety and Efficacy of Virtual Reality Graded Motor Imagery for Chronic Pain
Not yet recruiting NCT06294821 - 4AP to Delay Carpal Tunnel Release (CTR) Phase 2/Phase 3
Not yet recruiting NCT04328805 - Pain Reduction and Changes in Upper Limb Function Produced by an Ibuprofen Treatment in Carpal Tunnel Syndrome. Phase 4
Terminated NCT02791529 - Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release Phase 1
Completed NCT02141035 - Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome Phase 2/Phase 3
Completed NCT01887145 - Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome N/A
Recruiting NCT01897272 - Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study N/A
Completed NCT01394822 - Neuromuscular Ultrasound for Focal Neuropathies N/A